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Abstract
Background: Vaccine literature indexing is poorly performed in PubMed due to limited hierarchy of Medical
Subject Headings (MeSH) annotation in the vaccine field. Vaccine Ontology (VO) is a community-based biomedical
ontology that represents various vaccines and their relations. SciMiner is an in-house literature mining system that
supports literature indexing and gene name tagging. We hypothesize that application of VO in SciMiner will aid
vaccine literature indexing and mining of vaccine-gene interaction networks. As a test case, we have examined
vaccines for Brucella, the causative agent of brucellosis in humans and animals.
Results: The VO-based SciMiner (VO-SciMiner) was developed to incorporate a total of 67 Brucella vaccine terms. A
set of rules for term expansion of VO terms were learned from training data, consisting of 90 biomedical articles
related to Brucella vaccine terms. VO-SciMiner demonstrated high recall (91%) and precision (99%) from testing a
separate set of 100 manually selected biomedical articles. VO-SciMiner indexing exhibited superior performance in
retrieving Brucella vaccine-related papers over that obtained with MeSH-based PubMed literature search. For
example, a VO-SciMiner search of “live attenuated Brucella vaccine” returned 922 hits as of April 20, 2011, while a
PubMed search of the same query resulted in only 74 hits. Using the abstracts of 14,947 Brucella-related papers,
VO-SciMiner identified 140 Brucella genes associated with Brucella vaccines. These genes included known protective
antigens, virulence factors, and genes closely related to Brucella vaccines. These VO-interacting Brucella genes were
significantly over-represented in biological functional categories, including metabolite transport and metabolism,
replication and repair, cell wall biogenesis, intracellular trafficking and secretion, posttranslational modification, and
chaperones. Furthermore, a comprehensive interaction network of Brucella vaccines and genes were identified. The
asserted and inferred VO hierarchies provide semantic support for inferring novel knowledge of association of
vaccines and genes from the retrieved data. New hypotheses were generated based on this analysis approach.
Conclusion: VO-SciMiner can be used to improve the efficiency for PubMed searching in the vaccine domain.
Background
Since the introduction of Edward Jenner’s vaccine
against smallpox in 1796, vaccines have proven useful in
their ability to stimulate the immune system and confer
protection against infections by pathogenic microorgan-
isms. As such, vaccines provide safe, effective, and cost-
effective means to reduce the incidence of infectious dis-
eases. Vaccine research and development has undergone
a renaissance in recent years. This is in part attributable
to the cost-effectiveness of vaccines and advanced post-
genomic technologies [1]. Infectious diseases remain a
major source of morbidity and mortality worldwide,
causing 14.7 million deaths (26% of total global mortal-
ity) in 2001 [2]. Although considerable progress has
been made, vaccination against many medically impor-
tant pathogens, such as Human immunodeficiency virus
(HIV) and Brucella, has been unsuccessful due to their
unique mechanisms of pathogenesis [3,4]. For rational
vaccine design, extensive research is required to better
understand the pathogenesis and protective immune
responses against such diseases [5].
As the field of vaccine research continues to grow, the
amount of vaccine literature is rapidly increasing. Search
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of the biomedical literature database PubMed (http://
www.ncbi.nlm.nih.gov/pubmed) revealed the number of
vaccine-related citations has almost doubled over the
last decade (from 99,316 papers before 2000 to over
196,055 papers as of April 20, 2011). Due to this rapid
growth of published information, it is no longer feasible
to keep up to date with all the new literature manually,
even within one’s own research area. The field of litera-
ture mining, a means of computer-assisted information
extraction from literature data, is becoming increasingly
important to cope with the expanding volume of avail-
able biomedical literature. Articles in PubMed are
indexed with NLM-developed Medical Subject Headings
(MeSH), which is a controlled vocabulary of over 25,000
terms organized in a hierarchical fashion with 15 top-
level categories [6]. New articles deposited into PubMed
will be read by human experts and indexed with rele-
vant MeSH terms to represent the content. The use of
MeSH indexing in PubMed provides a consistent way to
retrieve information that may use different terminologies
for the same concepts. However, MeSH does not thor-
oughly cover many biomedical domains, including the
vaccine domain. For example, “Brucella vaccine” is cur-
rently the lowest level term under ‘vaccines’ in the
MeSH hierarchy. No individual Brucella vaccines are
currently indexed by MeSH. Furthermore, as a con-
trolled vocabulary, instead of a biomedical ontology,
MeSH does not contain logic definitions for the rela-
tions between different terms.
A biomedical ontology represents the consensus-based
controlled vocabularies of terms and relations, which are
logically formulated to promote intelligent information
retrieval and modeling. The Vaccine Ontology (VO;
http://www.violinet.org/vaccineontology) [7] is a com-
munity-based ontology in the domain of vaccine and
vaccination. VO classifies existing vaccines in licensed
use, on trial, or in research. The relations between dif-
ferent VO terms have been logically defined and support
advanced semantic reasoning. SciMiner is a web-based
literature mining tool developed for target (gene and
protein) identification and as well for functional enrich-
ment analysis [8,9]. SciMiner uses dictionary and rule-
based approaches for literature mining. We hypothe-
sized that a VO-based SciMiner literature mining pro-
gram would dramatically improve vaccine literature
indexing and support literature-based discovery of vac-
cine-gene interaction networks.
As a case study, we have focused on Brucella, an
intracellular bacterium that causes brucellosis, the most
common zoonotic disease worldwide [10]. Using the
VIOLIN vaccine database and analysis system [11], we
previously studied Brucella vaccines using multiple
bioinformatics approaches [12]. This study introduced
the manual curation of Brucella vaccines in the VIOLIN
database and in the VO and the online query system of
annotated Brucella vaccine information. However, there
has not been a systematic study on how to use the
curated Brucella vaccine terms and hierarchy in VO for
natural language processing (NLP)-based indexing of
Brucella vaccine literature, analysis of vaccine-associated
Brucella genes, and the prediction of the interaction
network between vaccines and Brucella genes. Such
study would significantly improve our understanding of
Brucella vaccinology and provide a use case for ontol-
ogy-based text mining in the field of vaccinology and
immunology.
In this study, a VO-based SciMiner approach (VO-Sci-
Miner) was developed, 1) to retrieve and index vaccine
names and Brucella genes from PubMed articles, and 2)
further identify and analyze interactions between Bru-
cella vaccines and Brucella genes. These studies revealed
that VO-SciMiner efficiently indexed Brucella vaccine
publications and generated a comprehensive vaccine-
gene interaction network.
Methods
Brucella vaccine terms and their semantic relations
All Brucella vaccine terms and their semantic relations
available in VO (http://www.violinet.org/vaccineontol-
ogy) were used in this study. The current version consist-
ing of 67 Brucella VO terms (as of April 2011) and their
synonyms were added to the dictionary of VO-SciMiner.
Term expansion rules of Brucella VO terms in SciMiner
A training set consisting of 90 papers with manually
confirmed Brucella vaccine VO terms was used to opti-
mize SciMiner for VO term identification. Patterns of
variations of VO terms in the actual text were learned
and implemented in VO-SciMiner as a series of term
expansion rules to maximize the power of term identifi-
cation. Examples of rules are below:
(1) Variations of functional words are used. For exam-
ple, “encoding” in the vaccine name can be replaced
with “coding for”.
(2) Unabbreviated gene names can be used instead of
abbreviated gene symbols (e.g., trigger factor for TF).
(3) VO terms with a full pathogen name (e.g., Brucella
abortus strain 19) can be abbreviated (e.g., B. abortus
strain 19) or abbreviated names can be fully spelled out.
(4) The word “strain(s)” can be added. For example,
“Brucella melitensis strain Rev. 1” can be an alternative
form for “Brucella melitensis Rev. 1”.
(5) Pathogen names can be removed. For example,
“Rev. 1” is frequently used without “Brucella melitensis“
in the text for “Brucella melitensis Rev. 1”.
(6) Spaces and special characters can be altered. For
example, “Rev.1”, “Rev1”, “Rev-1” and “Rev-I” can be
used as additional terms for “Rev. 1”.
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(7) Any SciMiner-identified VO term is ignored if a
corresponding genus or disease name does not appear in
the text. SciMiner reports identified Brucella VO terms
only if there is at least one occurrence of “Brucella“ or
“brucellosis” in any part of the text. This restriction helps
to improve the precision of the analysis by removing
potentially non-specific identification from other species.
Performance evaluation of VO-SciMiner
To evaluate the performance of VO-SciMiner in litera-
ture indexing, 50 negative and 50 positive papers were
manually compiled. Each paper in the positive set had at
least one confirmed Brucella VO term and contained a
total of 89 confirmed paper-VO associations, defined as
the “gold standard”. The paper set lacking Brucella vac-
cine terms, but still in the domain of Brucella or brucel-
losis, was used as a negative control. Performance was
measured by recall, precision, and F-measure (defined
below), where the paper-VO associations that matched
the gold standard constituted true positives (TP), asso-
ciations that did not match were false positives (FP),
and the gold standard associations that were not
matched were false negatives (FN) [13].
Recall (R) = TP/ (TP + FN)
Precision (P) = TP/ (TP + FP)
F − measure = (2 ∗ P ∗ R) / (P + R)
Indexing of PubMed abstracts with Brucella VO terms
using VO-SciMiner
In order to assess the improved information retrieval
using ontology-based indexing, VO-SciMiner was
applied to a subset of PubMed abstracts. For the present
analyses, a total of 14,947 Brucella related papers
(defined by “Brucella OR brucellosis” in PubMed as of
April 20, 2011) were processed and indexed by SciMi-
ner. The results were compared with PubMed search
results using the corresponding VO terms as queries.
Brucella gene name identification from literature
The NCBI RefSeq database contains 10 fully sequenced
and annotated Brucella genomes, which share more than
95% sequence homology [14]. However, since these gen-
omes have been independently annotated by multiple
research groups, orthologous genes from various Brucella
genomes frequently have different gene names (including
synonyms) and annotations. To retrieve all relevant lit-
erature associated with individual Brucella genes, we
used OrthoMCL-DB [15] to identify the orthologs among
different Brucella genomes. After removing redundant
terms, gene names and annotations were merged for
individual orthologs. For genes with variable names
across different Brucella genomes, the most frequently
used gene name was selected as the representative name;
other names were included as synonyms.
Identification of protein localization and over-represented
biological functions
The protein subcellular localization of these genes was
predicted by our reverse vaccinology program Vaxign
[16], which employs PSORTb 3.0, an open-source soft-
ware for subcellular localization prediction with high
accuracy (precision values > 97% and recall values >
94% based on benchmark evaluations) [17]. To deter-
mine the over-represented roles of identified Brucella
genes associated with Brucella vaccines, an enrichment
analysis using the Cluster of Orthologous Group (COG,
http://www.ncbi.nlm.nih.gov/COG) information was
employed [10,18]. Fisher’s exact [19] test was used to
calculate the statistical significance of these COG func-
tional groups (p-value < 0.05).
Identification of Brucella vaccines and genes interaction
Network
VO-SciMiner was applied to 14,947 Brucella papers to
identify Brucella genes and vaccines (VO). If a Brucella
gene name and a VO vaccine term were identified in the
same document (at the abstract level), a co-citation con-
nection was established between the gene and vaccine.
The complete Brucella gene-vaccine network was visua-
lized in Cytoscape [20], an open source bioinformatics
software for visualizing molecular interaction networks.
Each gene name and VO vaccine term is represented as a
node in the network. The number of papers for each co-
citation is represented as thickness of each edge.
Web-based implementation of VO-SciMiner
A VO-SciMiner website (http://www.violinet.org/vo-sci-
miner) has been developed to allow users to search Bru-
cella vaccine papers indexed with VO terms. This
website uses PHP on a Linux web server. A MySQL
database server is used to store network information. A
virtuoso Resource Description Framework (RDF) store is
used to store the contents of VO, including asserted and
inferred VO hierarchies. A cron (a time-based job sche-
duler) job has been set up on the web server to retrieve
new Brucella-related publications from PubMed on a
weekly basis. Once retrieved, the publications will be
processed through the VO-SciMiner analysis workflow,
and the results will be placed in the MySQL database.
Results
Overall workflow of VO-based literature mining approach
Figure 1 illustrates the proposed workflow of the VO-
SciMiner system. Pathogen-related literature is collected
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through PubMed. The titles and abstracts of the
retrieved documents are pre-processed by a sentence
splitter, and analyzed by the VO-SciMiner to identify
vaccine VO terms and pathogen gene names. The asso-
ciations of these vaccines and pathogen genes are
further analyzed via a vaccine-gene network visualized
with Cytoscape. Over-represented biological functions of
pathogen genes are examined using the COG
information.
Asserted and inferred VO hierarchies
The design of VO is based on OBO (Open Biological and
Biomedical Ontologies) Foundry Principles [21]. VO uti-
lizes the Basic Formal Ontology (BFO), a domain-inde-
pendent ontology, as an upper level ontology [7]. The
relation terms defined in the Relation Ontology (RO) are
used in VO for representing commonly used relation-
ships. Each subclass found in VO has an “is_a“ relation-
ship with its parent class. This characteristic ensures that
all vaccine subclasses (e.g., Brucella RB51) are included
when a parent class (e.g., “Brucella vaccine”) is searched.
Different types of vaccines are classified based on the
asserted VO vaccine hierarchy (Figure 2A) and inferred
VO vaccine hierarchy (Figure 2B). The asserted ontology
hierarchy is an ontology hierarchy specified by ontology
developers. The inferred ontology hierarchy, based on
the Web Ontology Language (OWL) [20], is generated
by a specific ontology reasoner, such as HermiT (http://
hermit-reasoner.com). An ontology reasoner infers logi-
cal consequences from a set of asserted facts based on
necessary and sufficient conditions. If an ontology term
is a member of an ontology class, then the term must
fulfill the class’s necessary conditions. Some classes may
also have sufficient conditions, and in those cases the
combination of necessary and sufficient conditions
makes an ontology class a fully defined class. For exam-
ple, the class term live attenuated vaccine is fully
defined as [’live vaccine’ and (has_quality some attenu-
ated)]. Many vaccines have the characteristics (necessary
condition) of being attenuated. For example, RB51 has
the following necessary condition [has_quality some
attenuated]. RB51 and many other vaccines are also live
Sentence preprocessing
(tle, abstract)
PubMed Literature
Pathogen
gene-vaccine associaon 
network
Vaccine-
associated genes
Explicit
VO term 
tagging
Implicit VO term 
tagging via VO 
hierarchy
Pathogen 
gene name 
tagging
Extended gene-vaccine 
associaon network Gene 
enrichment 
analysis
Orthologue
analysis
Vaccine Ontology
terms
RefSeq
Pathogen genes
Figure 1 Overall VO-SciMiner workflow.
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vaccines (another necessary condition). These two
necessary conditions are sufficient to define live attenu-
ated vaccine. Therefore, based on the logical definition,
the VO term RB51 can be inferred as a live attenuated
vaccine. Since RB51 is also a Brucella vaccine, it can be
further inferred as a live attenuated Brucella vaccine.
Such classification can only be obtained by an ontology
inferring since RB51 is not originally asserted as such
(Figure 2A).
Performance evaluation of VO term identification using
VO-SciMiner
To test the performance of SciMiner, 50 negative and 50
positive papers were manually compiled. The positive
set had 89 confirmed paper-VO associations, whereas
the negative set contained no VO terms. In this testing
set of 100 papers, VO-SciMiner identified 82 paper-VO
associations, of which 81 belonged to the gold standard
set, thereby achieving 91% recall, 99% precision, and
95% F-measure (Table 1).
VO-based indexing of Brucella vaccine papers using VO-
SciMiner
Literature indexing provides researchers with a means to
navigate efficiently through a network of scholarly scien-
tific articles in a subject domain. VO-SciMiner was
employed to index Brucella papers with Brucella vaccine
ontologies. For comparison purposes, typical PubMed
searches were conducted using corresponding terms
(Table 2). When no hierarchical VO structure informa-
tion was used, SciMiner performed in a manner similar
to that of a typical PubMed search. For example, the
query of “Brucella vaccine” yielded 1,379 hits in
PubMed Entrez and 1,359 hits in SciMiner. However,
when the hierarchical structure of VO was used, VO-
SciMiner returned significantly more papers than the
typical PubMed searches. A PubMed search of “live atte-
nuated Brucella vaccine” returned 74 hits, while the
VO-based SciMiner search returned 922 hits. The pri-
mary reason for this increased number of hits is due to
the addition of papers indexed with the child (subclass)
vaccine terms, belonging to “live attenuated Brucella
vaccines” in the VO hierarchy (Figure 2). For some vac-
cine terms, the VO-based SciMiner search increased the
number of positive PubMed paper hits by up to 15-fold
(Table 2).
The differences in literature retrieval can be explained
by the differences in how query terms are interpreted.
The PubMed Entrez system interprets the query “live
attenuated Brucella vaccines” using MeSH-based query-
ing system (Figure 3). VO-SciMiner does not perform
such a complicated search. It uses the hierarchical struc-
ture of VO to include any subclass terms of a given
query. MeSH in the PubMed also has such a feature,
A B
Figure 2 Brucella vaccines in VO. (A) Asserted hierarchy; (B) Inferred hierarchy. These are Protégé screenshots of VO without (A) or with
reasoning using HermiT 1.3.2 (B).
Hur et al. BMC Immunology 2011, 12:49
http://www.biomedcentral.com/1471-2172/12/49
Page 5 of 18
but does not include detailed vaccine terminologies in
its vocabulary. In addition, as a formal ontology, VO
also has logical semantic relations that allow formation
of inferred classes for more advanced reasoning.
PubMed searches generally yielded high precision for
most of the specific Brucella vaccines (data not shown).
In some cases, however, our VO-based approach was
able to significantly improve the precision. For example,
a typical PubMed search using “Brucella suis (strain 2
OR S2)” had 63 hits as of April 20, 2011, while a corre-
sponding VO (VO_0000722; B. suis strain 2) was identi-
fied in only 18 out of 14,947 Brucella related papers.
Manual review of the results revealed that the PubMed
search had only 12 true positives out of 63 hits, while
VO-SciMiner indexing had 17 true positives out of 18
hits. This result demonstrates a significantly improved
precision can be obtained using VO-based SciMiner
indexing.
Identification of Brucella vaccine-associated genes
From 14,947 Brucella-related papers, 1,009 distinct
interactions between 51 Brucella vaccine VO terms and
140 Brucella genes were identified. Grouped based on
their functional annotations, the details of these 140
Brucella genes and their various annotations are listed
in Table 3. Based on sub-cellular localization annotation,
these 140 Brucella proteins are located in different sub-
cellular areas, including outer membrane (10 proteins),
cytoplasm (75 proteins), periplasm (10 proteins), cyto-
plasmic membrane (25 proteins), extracellular matrix (2
proteins) and unknown location (18 proteins).
Based on their roles in host-pathogen interactions, the
140 identified Brucella genes associated with Brucella
vaccines can be classified into three groups: (1) protec-
tive antigens, (2) virulence factors, and (3) unknown.
Protective antigens elicit a protective immune response,
and are frequently used for vaccine development. VO-
SciMiner identified all 14 known protective Brucella
antigens [12]. Virulence factors are expressed and
secreted by pathogens and often responsible for causing
diseases in the host. Out of the 140 Brucella genes asso-
ciated with Brucella vaccines, 46 are known Brucella
virulence factors based on the updated curation infor-
mation from the Brucella Bioinformatics Portal (BBP;
http://www.phidias.us/bbp) [10,22] (Table 3). In total, 81
Brucella genes are neither known protective antigens
nor virulence factors. Since these genes have been stu-
died in the context of Brucella vaccines, it seems possi-
ble that some of them are potential virulence factors
and/or protective antigens. For example, RopB has not
been implicated in inducing immune protection. How-
ever, our recent reverse vaccinology analysis using Vax-
ign [16] found that Brucella abortus RopB is a potential
Brucella adhesin with a probability of 0.815 [12]. This
could make RopB a promising target for future vaccine
development as a potential protective antigen.
A functional analysis of the 140 genes and their sub-
groups is critical to illustrate their association with Bru-
cella vaccine research. Brucella genes have been well
categorized with the COG system [18]. We performed a
functional enrichment analysis identifying significantly
over-represented COG categories within all 140 genes
or 46 virulence factors. These include: “carbohydrate
transport and metabolism”, “cell wall, membrane, and
envelope biogenesis”, “intracellular trafficking, secretion,
and vesicular transport”, and “posttranslational modifi-
cation, protein turnover, chaperones” (Table 4).
Interestingly, the COG category “replication, recombi-
nation and repair” is significantly over-represented in
the 140 genes (p-value = 0.001); however, this category
is not enriched in the virulence factor group (p-value =
0.428). In total, 14 out of 140 Brucella genes belong to
Table 1 Performance of VO-SciMiner literature mining
Testing set Gold-Standard VO-Paper association Identified by VO-SciMiner True Identification Recall Precision F-measure
Positive 50 89 81 81 91% 100% 95%
Negative 50 0 1 0
Total 89 82 81 91% 99% 95%
Table 2 VO-based indexing results using VO-SciMiner and PubMed (as of April 20, 2011)
VO-SciMiner without child VOs VO-SciMiner with child VOs
PubMed Search Keywords PubMed
Entrez
Total (only by
VO-SciMiner)
Common Total (only by
VO-SciMiner)
Common
Brucella vaccine 1,379 1,359 (0) 1,359 2,155 (790) 1,365
Live attenuated Brucella vaccine 74 85 (12) 73 922 (849) 73
Live attenuated Brucella abortus vaccine 52 50 (1) 49 736 (647) 49
Live attenuated Brucella melitensis vaccine 36 37 (1) 36 204 (168) 36
Live attenuated Brucella suis vaccine 5 5 (0) 5 23 (18) 5
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this category (Table 3). Among them, three genes (uvrA,
mutM, and recA) are known virulence factors. Many of
the remaining genes are virulence factors in other
pathogens. For example, XerD, an enzyme responsible
for resolving chromosomal multimers prior to chromo-
some segregation, is a virulence factor in E. coli and S.
aureus [23,24]. Mutations of gryA and parC are respon-
sible for generation of quinolone-resistance in many
bacteria (e.g., Pseudomonas aeruginosa) [25]. These two
genes are critical for antibiotics resistance in virulent
bacteria. Therefore, it is reasonable to hypothesize that
many of the genes in this category may be potential
Brucella virulence factors.
Identification of Brucella vaccine-associated gene
networks
Difference in the volume of the retrieved literature can
result in a substantial difference in obtainable knowledge.
If one is interested in establishing the interaction network
of pathogen genes and vaccines, the networks (co-citations
of gene and vaccine), based on the PubMed search and
the VO-SciMiner search, can be substantially different
(Figure 4). Using 74 papers retrieved by PubMed, the
interaction network between genes and live attenuated
Brucella vaccines is extremely limited (Figure 4A). Only
35 genes are associated with live attenuated Brucella vac-
cines. However, when the VO hierarchy of ‘live attenuated
Brucella vaccine’ (Figure 2) is considered, 89 (54 more)
genes are identified by VO-SciMiner (Figure 4B).
Similarly, without VO hierarchy, the Brucella vaccine-
gene network is relatively sparse (Figure 5A), including
only 580 vaccine-gene associations. When VO hierarchy
is incorporated, the Brucella vaccine-gene network
becomes more intense with 1,009 vaccine-gene associa-
tions (Figure 5B). This is equivalent to a 74% increase in
the number of vaccine-gene associations, resulting in a
more comprehensive gene-vaccine association network.
Three types of interactions are observed in the Bru-
cella vaccine-gene interaction networks (Figures 4 and
5). The first type of interaction is a vaccine-vaccine
association, which results from the asserted is_a hierar-
chy between a vaccine and its parent or child terms as
asserted in VO (e.g., Brucella abortus vaccine and Bru-
cella abortus vaccine RB51), or from the inferred VO
hierarchy, for example, live attenuated Brucella vaccine
and Brucella abortus vaccine RB51 (Figure 2).
Another type of interaction in the Brucella network is
vaccine-gene interaction. Many vaccine-gene interac-
tions are based on direct association identified from the
literature. Such an example would be an association
between Brucella RB51 strain vaccine and the wboA
gene [26]. Alternatively, further vaccine-gene interac-
tions are based on asserted or inferred hierarchy by VO
reasoning. Since RB51 is inferred to be a live attenuated
Brucella vaccine, an inferred association between live
attenuated Brucella vaccine and the wboA gene can be
made. Indeed, based on the finding of a wboA mutation
in RB51, many live attenuated Brucella vaccine
Entrez (A)
VO_0001134 live attenuated Brucella abortus vaccine (736 / 50)
 VO_0000021 Brucella abortus RB51 (208)
 VO_0000022 Brucella abortus strain 19 (550)
 VO_0000347 Brucella abortus bacA mutant (4)
 VO_0000386 attenuated Brucella abortus with deletion 
   of znuA (1)
 VO_0000404 Brucella abortus RB51WboA (2)
 VO_0000720 Brucella abortus strain RB51SOD (6)
 VO_0000723 Brucella abortus strain 45/20 (72)
 VO_0000826 Brucella abortus P39 deletion vaccine (1)
VO-SciMiner (A)
(live[All Fields])
 AND
(attenuated[All Fields])
 AND
( ("brucellosis, bovine"[MeSH Terms] OR
 ("brucellosis"[All Fields] AND "bovine"[All Fields]) OR
 "bovine brucellosis"[All Fields] OR
 ("brucella"[All Fields] AND "abortus"[All Fields]) OR
 "brucella abortus"[All Fields] OR
 "brucella abortus"[MeSH Terms] OR
 ("brucella"[All Fields] AND "abortus"[All Fields])
)
 AND
( "vaccines"[MeSH Terms] OR
 "vaccines"[All Fields] OR
 "vaccine"[All Fields]
)
Total 52 papers Total 736 papers
Figure 3 Comparison between the Entrez system and VO-based literature search approaches. An example of searching “live attenuated
Brucella abortus vaccine” is illustrated.
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Table 3 Brucella genes in the gene-VO network
Locus
Tag
Gene
symbol
Gene name # of
associated
VO terms
# of papers - All VO
terms (Live Attenuated
vaccines)
Virulence factor
or Protective
antigen
Sub-cellular
localization
(PSORTb 3.0 score)
Nucleotide transport and metabolism
BMEI0296 purE phosphoribosylaminoimidazole
carboxylase, catalytic subunit
11 4 (4) V U (2.00)
BMEI0295 purK phosphoribosylaminoimidazole
carboxylase ATPase subunit
4 1 (1) CM (7.88)
Signal transduction mechanisms
BMEI2035 bvrS sensor histidine kinase BvrS, putative 10 3 (1) V CM (10.00)
BMEI0190 ptsP phosphoenolpyruvate-protein
phosphotransferase
5 1 (1) C (9.97)
BMEI2036 bvrR DNA-binding response regulator BvrR,
putative
10 4 (2) V C (9.97)
Cell motility
BMEII0150 fliC flagellin family protein 5 3 (0) V E (9.71)
Transcription
BMEII0665 rnr exoribonuclease, VacB/RNase II family 6 1 (1) C (9.97)
BMEII0427 eryD erythritol transcriptional regulator 2 1 (0) C (8.96)
BMEII1116 vjbR transcriptional regulator, LuxR family 10 3 (2) V U (2.00)
BMEI0749 rpoB DNA-directed RNA polymerase subunit
beta
6 5 (1) C (9.97)
BMEI1649 ureG-1 urease accessory protein UreG 2 1 (0) C (9.97)
BMEI2036 bvrR DNA-binding response regulator BvrR,
putative
10 4 (2) V C (9.97)
Amino acid transport and metabolism
BMEII0404 leuB 3-isopropylmalate dehydrogenase 5 1 (1) C (9.97)
BMEI0101 cysK Cysteine synthase A 6 1 (1) V C (9.26)
BMEI1653 ureB-1 urease subunit beta 3 2 (0) C (9.26)
BMEII0561 gcvP glycine dehydrogenase 5 1 (0) V C (9.97)
BMEI1654 ureA-1 urease subunit gamma 3 2 (0) C (9.26)
BMEII0193 potA ABC transporter 6 3 (2) C (9.12)
BMEII1054 hisG ATP phosphoribosyltransferase catalytic
subunit
2 1 (0) C (9.97)
BMEII0205 dppF ABC transporter 6 3 (2) CM (7.88)
BMEI1324 pepN aminopeptidase N 5 1 (1) V C (9.12)
BMEII0407 asd aspartate-semialdehyde dehydrogenase 6 1 (0) C (9.97)
BMEI1652 ureC-1 urease subunit alpha 3 3 (0) C (9.97)
BMEI0933 cysK cysteine synthase A 6 1 (1) V C (9.97)
Secondary metabolites biosynthesis, transport and catabolism
BMEI1111 acpXL acyl carrier protein 5 2 (0) C (9.97)
BMEI1475 acpP acyl carrier protein 5 1 (0) C (9.26)
BMEI0546 pncA pyrazinamidase/nicotinamidase 2 1 (0) V C (9.97)
Cell wall/membrane/envelope biogenesis
BMEI1829 ropB outer membrane protein, putative 23 37 (17) OM (10.00)
BMEI1237 galE epimerase/dehydratase family protein,
putative
6 3 (1) V C (8.96)
BMEI1249 omp25 outer-membrane protein Omp25 11 17 (4) V, P OM (10.00)
BMEI0402 omp31-
1
outer membrane protein Omp31 23 22 (9) P OM (10.00)
BMEII0844 omp31-
2
outer membrane protein, 31 kDa 19 17 (7) OM (10.00)
BMEI1413 gmd GDP-mannose 4,6-dehydratase 5 2 (0) V C (9.97)
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Table 3 Brucella genes in the gene-VO network (Continued)
BMEI0997 wbdA glycosyl transferase, group 1 family
protein
16 3 (1) V U (2.00)
BMEI1416 rfbE O-antigen export system ATP-binding
protein RfbE
6 3 (2) CM (7.88)
BMEII0847 wbjE putative glycosyltransferase 5 1 (0) U (2.00)
BMEI1393 wbpZ glycosyl transferase, group 1 family
protein
5 1 (0) V C (9.26)
BMEI1335 omp outer membrane lipoprotein-related
protein
12 5 (2) U (2.00)
BMEI0998 wboA glycosyl transferase WboA 17 16 (10) V C (8.96)
BMEI0340 pal lipoprotein, Pal family 12 7 (3) P OM (10.00)
BMEI0830 yaeT bacterial surface antigen 23 37 (17) OM (10.00)
BMEI1417 wbkB wbkB protein 5 2 (0) V U (2.00)
BMEI0509 lpcC lipopolysaccharide core biosynthesis
mannosyltransferase LpcC
9 2 (1) C (9.97)
BMEI1414 perA perosamine synthase, putative 10 3 (1) V C (9.97)
BMEII0837 hyaD glycosyl transferase, group 2 family
protein
5 1 (0) CM (9.82)
BMEI1404 wbkA mannosyltransferase, putative 16 7 (3) V C (9.26)
BMEII0253 mepA penicillin-insensitive murein
endopeptidase
5 1 (1) P (9.76)
Energy production and conversion
BMEII0404 leuB 3-isopropylmalate dehydrogenase 5 1 (1) C (9.97)
BMEI0474 petB ubiquinol-cytochrome c reductase,
cytochrome b
12 4 (2) CM (10.00)
BMEII0429 eryB glycerol-3-phosphate dehydrogenase 2 1 (0) V C (9.97)
BMEI0137 mdh malate dehydrogenase 5 1 (1) U (4.99)
BMEI0140 kgd alpha-ketoglutarate decarboxylase 11 8 (4) C (9.97)
BMEII0076 tycC enterobactin synthetase, component F,
putative
2 1 (0) C (9.97)
BMEI1547 atpI ATP sythase protein I, putative 6 1 (1) U (2.00)
Replication, recombination and repair
BMEI0147 xerC site-specific tyrosine recombinase XerC 5 1 (0) C (9.26)
BMEI0215 ialA dinucleoside polyphosphate hydrolase 1 1 (0) C (9.97)
BMEI0884 gyrA DNA gyrase subunit A 2 1 (0) C (9.97)
BMEI0040 xerD site-specific tyrosine recombinase XerD 5 2 (0) C (9.97)
BMEI0880 ssb single-stranded DNA-binding protein
family
5 2 (1) C (9.26)
BMEI1823 gyrB DNA gyrase subunit B 2 1 (0) C (9.97)
BMEI1200 parC DNA topoisomerase IV subunit A 2 1 (0) C (9.12)
BMEI0878 uvrA excinuclease ABC subunit A 5 2 (1) V C (9.97)
BMEI1307 xerC site-specific recombinase, phage
integrase family
5 1 (0) C (9.97)
BMEII0676 parE DNA topoisomerase IV subunit B 2 1 (0) C (9.97)
BMEI1946 mutM formamidopyrimidine-DNA glycosylase 1 1 (0) V C (9.97)
BMEII0739 alkB alkylated DNA repair protein AlkB 6 1 (1) U (2.00)
BMEII0184 insN IS3 family element, transposase orfA 6 1 (1) U (2.00)
BR1202 recA recombinase A 2 1 (0) V C (10.00)
Posttranslational modification, protein turnover, chaperones
BMEI1650 ureF urease accessory protein UreF, putative 2 1 (0) U (2.00)
BMEII1047 groES co-chaperonin GroES 1 1 (0) C (9.97)
BMEI1041 sufC ABC transporter, ATP-binding protein 6 3 (2) C (9.97)
BMEI2001 dnaJ chaperone protein DnaJ 1 1 (0) C (9.97)
BMEI1330 htrA serine protease 7 6 (3) V P (9.76)
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Table 3 Brucella genes in the gene-VO network (Continued)
BMEI2002 dnaK molecular chaperone DnaK 12 7 (2) V, P C (9.97)
BMEII1048 groEL chaperonin GroEL 10 9 (5) C (9.97)
BMEI1655 ureD-1 urease accessory protein UreD 3 2 (0) C (9.26)
BMEI1649 ureG-1 urease accessory protein UreG 2 1 (0) C (9.97)
BMEII0401 trx-2 thioredoxin 5 2 (1) C (9.26)
BMEI1069 tig trigger factor 10 2 (0) V, P C (8.96)
BMEI1651 ureE urease accessory protein UreE 2 1 (0) C (9.97)
BMEI1060 dsbA outer membrane protein, putative 23 37 (17) V U (2.00)
BMEI2022 trx-1 thioredoxin 5 2 (1) C (9.26)
BMEI1265 surA peptidyl-prolyl cis-trans isomerase,
putative
9 1 (1) P P (9.76)
BMEI1492 exsA ABC transporter, ATP-binding/permease
protein
6 1 (1) V CM (10.00)
Translation, ribosomal structure and biogenesis
BMEI2010 infC translation initiation factor IF-3 2 2 (0) C (9.97)
BMEI0826 frr ribosome recycling factor 5 2 (1) C (9.97)
BMEI0748 rplL 50S ribosomal protein L7/L12 16 17 (6) P U (6.49)
BMEI0752 rpsL 30S ribosomal protein S12 5 1 (1) C (9.26)
BMEI1497 tlyA hemolysin A 1 2 (0) C (8.96)
Inorganic ion transport and metabolism
BMEII0003 modC molybdenum ABC transporter, ATP-
binding protein
6 3 (2) C (9.12)
BMEII0893 katA catalase 6 2 (0) P (10.00)
BMEII0177 znuC zinc ABC transporter, ATP-binding
protein
6 3 (2) V CM (7.88)
BMEI0790 phoA bacterial alkaline phosphatase 9 7 (2) P (10.00)
BMEII0581 sodC superoxide dismutase, Cu-Zn 15 14 (8) V, P P (10.00)
BMEI1292 fsr fosmidomycin resistance protein 2 1 (0) CM (10.00)
BMEII0108 tauB taurine ABC transporter, ATP-binding
protein
6 3 (2) CM (9.98)
BMEI0635 cbiO cobalt ABC transporter, ATP-binding
protein
6 3 (2) CM (9.82)
BMEII0704 bfr bacterioferritin 12 4 (2) P C (9.97)
BMEII0178 znuA zinc ABC transporter, periplasmic zinc-
binding protein
9 1 (1) V P (9.76)
Coenzyme transport and metabolism
BMEII0589 ribH riboflavin synthase subunit beta 12 8 (0) C (9.97)
BMEI2029 ahcY S-adenosyl-L-homocysteine hydrolase 4 1 (1) C (9.97)
BMEI1099 cobT nicotinate-nucleotide–
dimethylbenzimidazole
phosphoribosyltransferase
2 1 (0) C (9.97)
BMEI1187 ribH riboflavin synthase subunit beta 12 8 (0) C (9.97)
Cell cycle control, cell division, chromosome partitioning
BMEII0470 crcB crcB family protein 5 1 (0) CM (10.00)
General function prediction only
BMEII0288 oppF peptide ABC transporter, ATP-binding
protein
6 3 (2) CM (9.99)
BMEI1081 surE stationary phase survival protein SurE 8 5 (2) C (8.96)
BMEI0215 ialA dinucleoside polyphosphate hydrolase 1 1 (0) C (9.97)
BMEI0920 mazG nucleoside triphosphate
pyrophosphohydrolase
5 1 (0) C (8.96)
BMEI1584 ialB invasion protein B 1 2 (0) P U (2.50)
BMEII0355 gal D-galactose 1-dehydrogenase, putative 5 1 (0) C (9.97)
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Table 3 Brucella genes in the gene-VO network (Continued)
Lipid transport and metabolism
BMEI1111 acpXL acyl carrier protein 5 2 (0) C (9.97)
BMEI1553 bacA transport protein 9 5 (4) V CM (10.00)
BMEI1475 acpP acyl carrier protein 5 1 (0) C (9.26)
Carbohydrate transport and metabolism
BMEII0983 chvE sugar ABC transporter, periplasmic
sugar-binding protein, putative
9 1 (1) U (5.02)
BMEI1394 manA mannose-6-phosphate isomerase 5 1 (0) C (8.96)
BMEI1237 galE epimerase/dehydratase family protein,
putative
6 3 (1) V C (8.96)
BMEII0430 eryA erythritol kinase 5 2 (1) C (9.26)
BMEI0310 gap glyceraldehyde-3-phosphate
dehydrogenase
5 1 (1) C (9.97)
BMEII0750 smoK sugar ABC transporter, ATP-binding
protein
6 3 (2) CM (9.99)
BMEI1416 rfbE O-antigen export system ATP-binding
protein RfbE
6 3 (2) CM (7.88)
BMEII0940 smoK sugar ABC transporter, ATP-binding
protein
6 3 (2) CM (9.99)
BMEII0625 ugpB glycerol-3-phosphate ABC transporter,
periplasmic glycerol-3-phosphate-
binding protein
1 1 (0) V P (9.76)
BMEI0309 pgk phosphoglycerate kinase 6 1 (1) C (9.97)
BMEII0899 manB phosphoglucomutase, putative 10 3 (1) V C (9.26)
BMEII0428 eryC D-erythrulose-1-phosphate
dehydrogenase
9 2 (1) V C (8.96)
ABM67295 P39 immunogenic 39-kDa protein 15 7 (3) P P (9.44)
BMEII0982 rbsA sugar ABC transporter, ATP-binding
protein, putative
5 1 (1) CM (9.82)
BMEII0355 gal D-galactose 1-dehydrogenase, putative 5 1 (0) C (9.97)
BMEI1396 pmm phosphomannomutase, putative 10 5 (1) V C (9.97)
BMEII0145 xylG D-xylose ABC transporter, ATP-binding
protein
6 3 (2) CM (7.88)
BMEI1886 pgm phosphoglucomutase 9 2 (1) V C (8.96)
BMEII0251 glk glucokinase 5 1 (1) C (9.97)
Intracellular trafficking, secretion, and vesicular transport
BMEI1077 yajC preprotein translocase, YajC subunit 6 1 (1) CM (9.82)
BMEI1076 secD protein-export membrane protein, SecD/
SecF family
6 1 (1) CM (10.00)
BMEII0026 virB2 type IV secretion system protein VirB2 9 3 (1) V CM (9.46)
BMEII0028 virB4 type IV secretion system protein VirB4 9 4 (1) V CM (10.00)
BMEII0029 virB5 type IV secretion system protein VirB5 9 1 (1) V U (2.00)
BMEII0032 virB8 type IV secretion system protein VirB8 9 1 (0) V U (2.00)
BMEII0025 virB1 type IV secretion system protein VirB1 5 1 (0) V E (9.64)
BMEII0034 virB10 type IV secretion system protein VirB10 5 1 (1) V U (4.90)
Unclassified (function unknown)
CAA86936 BLS Brucella lumazine synthase 19 12 (2) P C (9.97)
BMEI1305 omp2b porin Omp2b 16 21 (9) OM (9.93)
BMEI1306 omp2a porin Omp2a 13 17 (8) OM (9.93)
BMEI0135 omp19 lipoprotein Omp19 12 10 (5) V, P OM (10.00)
BMEII0017 omp10 lipoprotein Omp10 9 6 (2) V OM (10.00)
BMEI0536 omp28 immunoreactive 28 kDa outer
membrane protein
19 15 (11) P P (10.00)
BMEI0330 opgC opgC protein, putative 5 1 (1) CM (10.00)
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candidates, such as VTRS1 and VTRM1 [27], have been
developed by mutating the wboA sequence in various
wild type Brucella strains.
The present study also reveals that four B. suis vac-
cine-gene interactions are isolated from the other inter-
actions, suggesting that these vaccine-gene interactions
were only studied in the context of B. suis, but not for
other Brucella species. The inferred vaccine-gene asso-
ciations are potentially valuable for systematic analysis
of genes associated with less-specific type of vaccines (e.
g., live attenuated Brucella vaccines) instead of specific
vaccines such as RB51.
The last type of interaction in the Brucella network is
gene-gene interaction. The obvious gene-gene interac-
tions in a network are found between those genes co-
cited in the same paper(s). In addition, many new gene-
gene interactions can be inferred through their associa-
tion with the same vaccines. In a gene-gene interaction
network under the scope of live attenuated Brucella vac-
cine based on PubMed search (Figure 4A), two genes in
a two-component system, bvrR and bvrS are associated,
and are linked to one gene, wbkA (Figure 4A). When
the vaccine hierarchy was used in VO-SciMiner, eight
more genes were detected that are associated with bvrR
and bvrS under the same scope of live attenuated Bru-
cella vaccine. VO-SciMiner also detects what specific
live attenuated Brucella vaccines (e.g., B. abortus vaccine
RB51) interact with a gene (e.g., wboA). New hypotheses
can also be generated based on the gene-gene network
under a Brucella vaccine domain. For example, Brucella
bvrS and bvrR are only associated directly with B. abor-
tus vaccines (Figure 4A and 4B). However, many genes
(e.g., wbdA and wbkA) that interact with bvrS and bvrR
are also associated with live attenuated B. melitensis and
B. suis vaccines. Therefore, it is reasonable to hypothe-
size that the mutants of bvrR or bvrS gene in B. meliten-
sis and B. suis may also be candidates for live attenuated
Brucella vaccines.
A web server for browsing and analyzing VO-SciMiner
literature mining results
A web-based application of VO-SciMiner-based Brucella
paper indexing has been developed (http://www.violinet.
org/vo-sciminer). This webpage provides two ways to
explore the Brucella vaccine literature (Figure 6A). The
first option is to select a vaccine using the dropdown list.
Table 3 Brucella genes in the gene-VO network (Continued)
BMEI0634 crcB crcB family protein 5 1 (0) CM (10.00)
BMEI0545 pncA hypothetical protein 5 1 (0) V CM (10.00)
Note: Sub-cellular localization was predicted using PSORTb 3.0 implemented in Vaxign. PSORTb score ranges from 0 (0% probability) to 10 (100% probability).
Proteins with a score below 7.44 are classed as unknown. The abbreviations in this table are C (Cytoplasmic), CM (CytoplasmicMembrane), E (Extracellular), OM
(OuterMembrane), P (Periplasmic) and U (Unknown).
Table 4 COG functional analysis of Brucella genes associated with vaccine research
VO-associated Genes
(n = 140)
Virulent Genes
(n = 46)
COG Description # of genes (p-value) # of genes (p-value)
Amino acid transport and metabolism 12 (0.771) 4 (1.000)
Carbohydrate transport and metabolism 19 (0.000*) 6 (0.043*)
Cell cycle control, cell division, chromosome partitioning 1 (1.000)
Cell motility 1 (1.000) 1 (0.341)
Cell wall/membrane/envelope biogenesis 22 (0.000*) 9 (0.001*)
Coenzyme transport and metabolism 4 (0.820)
Energy production and conversion 5 (0.843) 1 (0.728)
Inorganic ion transport and metabolism 10 (0.149) 3 (0.475)
Intracellular trafficking, secretion, and vesicular transport 7 (0.003*) 5 (0.000*)
Lipid transport and metabolism 3 (0.627) 1 (1.000)
Nucleotide transport and metabolism 2 (0.769) 1 (1.000)
Posttranslational modification, protein turnover, chaperones 16 (0.000*) 5 (0.025*)
Replication, recombination and repair 14 (0.001*) 3 (0.428)
Secondary metabolites biosynthesis, transport and catabolism 3 (0.750) 1 (0.601)
Signal transduction mechanisms 3 (1.000) 2 (0.357)
Transcription 6 (0.704) 2 (1.000)
Translation, ribosomal structure and biogenesis 5 (0.684)
Note: * indicates p < 0.05.
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A list of publications related to the selected vaccine will be
displayed on the lower right panel when the search button
is clicked. For each publication, VO-SciMiner lists the
PubMed ID, the title, and an abstract if available. In the
abstract section, all the related vaccines and genes are
highlighted and linked to a page containing detailed
information of corresponding vaccines and genes. Another
way to select a vaccine is by navigating through the hier-
archical structure of different vaccines on the lower left
panel. This panel lists all the Brucella vaccines on an
inferred tree structure. If available, two numbers will be
shown for each node. The first number is the total number
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of publications related to this node and any of its child
nodes. The second number shows the number of publica-
tions related only to this node. If any of the numbers are
clicked, the lower right panel will display a detailed list of
publications. A hyperlink ‘Show interactions network’ will
appear at the top of the screen. This will bring up a new
display of the vaccine and gene interaction network (Fig-
ure 6B).
Discussion
The present study demonstrates that the application of
Vaccine Ontology in literature mining enhances the
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retrieval of Brucella vaccine literature. Term variation
rules, inclusion vaccine synonyms, and the inference of
vaccine terms through the hierarchy increases the
amount of literature that can be retrieved. VO-based
SciMiner is capable of identifying up to 15 times more
Brucella vaccine papers than the typical PubMed search
using the Entrez system. The increase in the retrieved
literature results in the generation of a comprehensive
co-citation network of Brucella genes and Brucella vac-
cines, revealing key vaccine-gene associations and pro-
vides potential valuable opportunities for the
development of new vaccines.
To our knowledge, this study is the first manuscript
that compares MeSH and specific domain ontology (e.g.,
Vaccine Ontology in this case) for literature indexing.
The results show that VO can be used to improve litera-
ture searching for Brucella vaccines. While MeSH pro-
vides reasonable searching specificity, its level of
sensitivity may be very low for many biomedical
research areas (e.g., vaccines). For example, “Brucella
vaccine” is currently one of the lowest level (the most
specific) terms in MeSH, and no individual Brucella vac-
cines such as RB51 are indexed by MeSH. In contrast,
VO-based SciMiner contains detailed vaccine terminolo-
gies in a controlled hierarchical structure, allowing
searches across the hierarchy, thereby achieving a very
significant recall.
Therefore, it is possible to substantially increase
PubMed searching sensitivity by incorporating ontology
information. Increased sensitivity in turn will result in
increasing the amounts of information obtained on any
given search topic. As illustrated in the gene-vaccine
networks in Figure 4, the level of obtainable information
from papers either retrieved by PubMed (A) and VO-
SciMiner (B) is substantial. Based on the hierarchy
structure of VO, the VO-based approach can retrieve a
more comprehensive network. Therefore, it is possible
to use a community-based ontology (e.g., VO) to
Save graph in SVG format  Save graph in GML format
live attenuated Brucella suis vaccine
wboA
wbdA
Brucella suis strain 2
omp2b
omp31-1
Brucella suis strain VTRS1
A
B C
Figure 6 Screen shot of VO-SciMiner webpage. Two panels are illustrated in this web page with “VO_0001136: live attenuated Brucella suis
vaccine” selected. The left panel shows the hierarchical structure of the ontology term ‘Brucella vaccine’ and its child terms in VO. Two numbers
are displayed next to each of the VO terms. The first number represents the total number of search hits including the research results from all
the child terms (if any) and the second number is the number of hits for the current term. Once either number is clicked, the abstract details are
displayed on the right panel. The identified VO terms and Brucella genes are highlighted.
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replace, or enhance, a part of a MeSH-based document
retrieval system such as PubMed in some domains (e.g.,
in vaccine).
Using ontologies to support literature mining has
become an active area of research over the last decade.
Multiple text-mining tools and web-resources, including
GoPubMed [28], SEGOPubMed [29], and GoWeb [30]
have been developed to link PubMed papers to ontolo-
gies, particularly Gene Ontology, within the biomedical
data. Using the domain knowledge and hierarchical
organization, these tools allow users to perform ontol-
ogy-based PubMed document browsing. However, they
are limited by lack of coverage in the vaccine domain as
in the PubMed Entrez search system. BioPortal (http://
bioportal.bioontology.org), a steadily growing online
resource developed by the National Center for Biomedi-
cal Ontology (NCBO), currently indexes multiple biome-
dical public resources. These include gene expression
and protein-protein interaction data sets, which are
comprised of over 250 ontologies and 4 million ontology
terms. The BioPortal provides a convenient web inter-
face. Unfortunately, PubMed biomedical literature is not
supported in the BioPortal yet. In this study, we demon-
strated that the newly developed VO provides a power-
ful system for ontology-based vaccine literature
indexing, through the dictionary- and rule-based VO-
SciMiner system. It offers the further advance of a sig-
nificantly enhanced recall and precision. The dictionary-
and rule-based literature mining system for optimization
of a vaccine term searching is not presently found in the
BioPortal or any other literature mining system.
In an effort to improve vaccine literature mining and
to support the vaccine research community, VO-SciMi-
ner has been integrated into the VIOLIN vaccine
research database and data analysis system (http://www.
violinet.org)[11]. VIOLIN includes all the vaccine litera-
ture from PubMed and provides multiple tools for navi-
gating various vaccines and relevant literature. These
tools include (1) Litesearch providing basic vaccine lit-
erature keyword searching feature; (2) Vaxmesh, a
MeSH-based visualization tool for displaying the MeSH
hierarchy and the numbers of vaccine papers associated
with each MeSH terms; (3) Vaxpresso, a VIOLIN vac-
cine literature mining program powered by Textpresso
natural language processing (NLP) program [31], for
identifying genes and proteins in literature data. Initially,
we intended to integrate VO into our Vaxpresso. How-
ever, Textpresso, the base system of Vaxpresso, had a
limitation of slow-execution since it is a plain text file-
based system rather than a relational database-based
program. Compared to these existing VIOLIN text
mining tools, VO-SciMiner is a significant extension
because it is the first NLP literature mining program
that integrates VO terms and VO hierarchy for efficient
vaccine literature indexing. This study also represents
the first effort to apply VO to studying the interaction
network between vaccines and microbial genes.
In addition to improving the retrieval of Brucella
vaccine-related papers by incorporating VO into Sci-
Miner, SciMiner was extended to identify Brucella
pathogen genes reported in the literature. Comprehen-
sive co-citation networks of Brucella vaccines and Bru-
cella genes were generated as illustrated in Figures 4
and 5. These comprehensive networks not only illus-
trate direct gene-vaccine associations co-cited in the
literature, but also reveal indirect associations inferred
through the VO hierarchy. These literature-based net-
works can enhance vaccine development, since they
allow the generation of additional hypotheses. As
demonstrated in this paper, many Brucella genes are
potential new protective antigens and/or virulence fac-
tors. Protective antigens are defined as those genes
that are able to induce protection in vivo. Mutation of
a virulence factor gene in Brucella results in an attenu-
ated mutant strain, which can be a potential live atte-
nuated vaccine. Therefore, it is suggestive that genes
identified by the presently described methodology can
serve possible targets for development of new Brucella
vaccines.
It should be noted that the text mining approach
implemented in VO-SciMiner has its own limitations.
The co-citation-based VO-SciMiner is still in an early
stage of being applied to the field of vaccinology
research. The identification of potential new gene-vac-
cine associations based on a text mining method may
include false-positives due to excellent but still imperfect
performance (an F-measure of 95%). Besides, co-citation
of both a gene and a vaccine in the same document
does not necessarily mean that they are functionally
associated. Therefore, any interesting association will
require careful consideration and experimental investi-
gation. In spite of these limitations, text mining studies
have proven useful in identifying previously unknown
knowledge such as predicted combinatorial binding of
transcriptional factors to regulatory elements [32], and
reconstructing protein-protein interactions and path-
ways [33].
Our current study has also generated predictions that
form new hypotheses for further experimental studies.
To make our current approach more robust, the gene-
vaccine text mining method may be improved in the
future by retrieving additional data, including the types
of interactions, the animal or cell types used, and speci-
fic experimental designs and conditions. Furthermore,
the text mining prediction approach becomes more
powerful and specific when it is integrated with other
computational and experimental methods such as
microarray and proteomics studies [34-36].
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Brucella vaccines were used as examples in this study.
In the near future, other bacterial vaccines will be added
to the VO-SciMiner system. Incorporating additional
rules for species other than Brucella may be challenging
if other bacterial vaccines have substantially different
structures than Brucella VOs. However, the Brucella
case study as presented provides a general strategy and
framework to address these issues. The VO-SciMiner
indexing strategy can also be used to improve other
gene interaction network studies. For example, previous
studies presented the retrieval of an IFN-g and vaccine-
mediated immune network based on a genome-wide
centrality-based literature discovery method [37], which
was improved by application of VO [38]. However, it is
suggestive that further improvements may be made in
the identification of vaccine and gene entities contained
in the literature using the VO-SciMiner indexing
approaches. The indexing of human and mouse genes
for studying the interactions between Brucella vaccines
and host genes is currently under investigation. The
approach taken in this study is generic and can be
applied to analyze other vaccines listed in VO.
Conclusions
We have developed a methodology that incorporates
Vaccine Ontology into literature mining to improve
relevant paper retrieval in the domain of vaccine
research. To test our methodology, Brucella vaccines
were used. Our analyses indicate that the VO-based Sci-
Miner method substantially increases retrieval of asso-
ciated data, leading to an improved analysis and
understanding of the vaccine-gene networks.
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